Related references
Note: Only part of the references are listed.Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Mark Kirschbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial
Takashi Watanabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results
Kensei Tobinai et al.
CANCER SCIENCE (2010)
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Ken Ohmachi et al.
CANCER SCIENCE (2010)
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Takashi Watanabe et al.
CANCER SCIENCE (2010)
Prognostic Factors in Follicular Lymphoma
Thomas Relander et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
K Tobinai et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2
P Bali et al.
CLINICAL CANCER RESEARCH (2005)
Differential protein acetylation induced by novel histone deacetylase inhibitors
KB Glaser et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: Results of a Japanese phase II study
M Ogura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
